132 related articles for article (PubMed ID: 32829413)
1. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis.
Tibaldi J; Pistorio A; Aldera E; Puzone L; El Miedany Y; Pal P; Giri PP; De H; Khubchandani R; Chavan PP; Vilaiyuk S; Lerkvaleekul B; Yamsuwan J; Sabui TK; Datta P; Pardeo M; Bracaglia C; Sawhney S; Mittal S; Hassan WA; Elderiny GF; Abu-Zaid MH; Eissa M; Sztajnbok F; das Neves Sztajnbok FC; Russo R; Katsicas MM; Cimaz R; Marrani E; Alexeeva E; Dvoryakovskaya TM; Alsuweiti MO; Alzyoud RM; Kostik M; Chikova I; Minoia F; Filocamo G; Farag Y; Lotfy H; Nasef SI; Al-Mayouf SM; Maggio MC; Magalhaes CS; Gallizzi R; Conti G; Shimizu M; Civino A; Felici E; Giancane G; Ruperto N; Consolaro A; Ravelli A
Rheumatology (Oxford); 2020 Nov; 59(11):3505-3514. PubMed ID: 32829413
[TBL] [Abstract][Full Text] [Related]
2. The association of MEFV gene mutations with the disease risk and severity of systemic juvenile idiopathic arthritis.
Zhong L; Wang W; Li J; Ma M; Gou L; Wang C; Yu Z; Zhang T; Dong Y; Wei Q; Song H
Pediatr Rheumatol Online J; 2020 May; 18(1):38. PubMed ID: 32398039
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a composite disease activity score for juvenile idiopathic arthritis.
Consolaro A; Ruperto N; Bazso A; Pistorio A; Magni-Manzoni S; Filocamo G; Malattia C; Viola S; Martini A; Ravelli A;
Arthritis Rheum; 2009 May; 61(5):658-66. PubMed ID: 19405003
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis.
Rosina S; Consolaro A; van Dijkhuizen P; Pistorio A; Varnier GC; Bovis F; Nistala K; Maillard S; Civino A; Tsitsami E; de Inocencio J; Jelusic M; Vojinovic J; Espada G; Makay B; Katsicas MM; Pratsidou-Gertsi P; Lazarevic D; Rao AP; Pires Marafon D; Martini A; Pilkington C; Ruperto N; Ravelli A
Rheumatology (Oxford); 2019 Jul; 58(7):1196-1205. PubMed ID: 30690571
[TBL] [Abstract][Full Text] [Related]
5. Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis.
Consolaro A; Ruperto N; Pistorio A; Lattanzi B; Solari N; Galasso R; Pederzoli S; Varnier GC; Dolezalova P; Alessio M; Burgos-Vargas R; Vesely R; Martini A; Ravelli A;
Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1262-70. PubMed ID: 21618454
[TBL] [Abstract][Full Text] [Related]
6. Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis.
McErlane F; Beresford MW; Baildam EM; Chieng SE; Davidson JE; Foster HE; Gardner-Medwin J; Lunt M; Wedderburn LR; Thomson W; Hyrich KL;
Ann Rheum Dis; 2013 Dec; 72(12):1983-8. PubMed ID: 23256951
[TBL] [Abstract][Full Text] [Related]
7. Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis.
Magni-Manzoni S; Cugno C; Pistorio A; Garay S; Tsitsami E; Gasparini C; Viola S; Ruperto N; Martini A; Ravelli A
Clin Exp Rheumatol; 2005; 23(3):421-5. PubMed ID: 15971436
[TBL] [Abstract][Full Text] [Related]
8. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
9. The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).
Demirkaya E; Ozen S; Sozeri B; Ayaz NA; Kasapcopur O; Unsal E; Makay BB; Barut K; Fidanci BE; Simsek D; Cakan M; Consolaro A; Bovis F; Ruperto N;
Rheumatol Int; 2018 Apr; 38(Suppl 1):395-402. PubMed ID: 29637329
[TBL] [Abstract][Full Text] [Related]
10. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Minoia F; Bovis F; Davì S; Horne A; Fischbach M; Frosch M; Huber A; Jelusic M; Sawhney S; McCurdy DK; Silva CA; Rigante D; Unsal E; Ruperto N; Martini A; Cron RQ; Ravelli A;
Ann Rheum Dis; 2019 Oct; 78(10):1357-1362. PubMed ID: 31296501
[TBL] [Abstract][Full Text] [Related]
11. The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).
Lazăr C; Iagăru N; Ailioaie C; Ailioaie LM; Laday M; Apostol A; Spîrchez M; Badiu Tișa I; Consolaro A; Bovis F; Ruperto N;
Rheumatol Int; 2018 Apr; 38(Suppl 1):331-338. PubMed ID: 29637333
[TBL] [Abstract][Full Text] [Related]
12. The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).
Consolaro A; Bovis F; Pistorio A; Cimaz R; De Benedetti F; Miniaci A; Corona F; Gerloni V; Martino S; Pastore S; Barone P; Pieropan S; Cortis E; Podda RA; Gallizzi R; Civino A; Torre F; Rigante D; Consolini R; Maggio MC; Magni-Manzoni S; Perfetti F; Filocamo G; Toppino C; Licciardi F; Garrone M; Scala S; Patrone E; Tonelli M; Tani D; Ravelli A; Martini A; Ruperto N;
Rheumatol Int; 2018 Apr; 38(Suppl 1):251-258. PubMed ID: 29637324
[TBL] [Abstract][Full Text] [Related]
13. Facilitating patient-centered care: the development of illustrated multidimensional patient-reported outcome measures for children/adolescents with juvenile idiopathic arthritis.
El Miedany Y; El Gaafary M; Lotfy H; El Aroussy N; Mekkawy D; Nasef SI; Elderiny G; Farag Y; Hassan M
Clin Rheumatol; 2019 Aug; 38(8):2219-2226. PubMed ID: 30834997
[TBL] [Abstract][Full Text] [Related]
14. The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).
Boyko Y; Hrytsiuk I; Consolaro A; Bovis F; Ruperto N;
Rheumatol Int; 2018 Apr; 38(Suppl 1):403-409. PubMed ID: 29637352
[TBL] [Abstract][Full Text] [Related]
15. Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease.
Ringold S; Bittner R; Neogi T; Wallace CA; Singer NG
Arthritis Care Res (Hoboken); 2010 Aug; 62(8):1095-102. PubMed ID: 20506561
[TBL] [Abstract][Full Text] [Related]
16. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting.
Nordal EB; Zak M; Aalto K; Berntson L; Fasth A; Herlin T; Lahdenne P; Nielsen S; Peltoniemi S; Straume B; Rygg M
Ann Rheum Dis; 2012 Jul; 71(7):1122-7. PubMed ID: 22258487
[TBL] [Abstract][Full Text] [Related]
17. Patient factors associated with waiting time to pediatric rheumatologist consultation for patients with juvenile idiopathic arthritis.
Barber CEH; Barnabe C; Benseler S; Chin R; Johnson N; Luca N; Miettunen P; Twilt M; Veeramreddy D; Shiff NJ; Schmeling H
Pediatr Rheumatol Online J; 2020 Mar; 18(1):22. PubMed ID: 32143720
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis.
Viola S; Felici E; Magni-Manzoni S; Pistorio A; Buoncompagni A; Ruperto N; Rossi F; Bartoli M; Martini A; Ravelli A
Arthritis Rheum; 2005 Jul; 52(7):2092-102. PubMed ID: 15986372
[TBL] [Abstract][Full Text] [Related]
19. Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score.
Consolaro A; Ruperto N; Bracciolini G; Frisina A; Gallo MC; Pistorio A; Verazza S; Negro G; Gerloni V; Goldenstein-Schainberg C; Sztajnbok F; Wulffraat NM; Martini A; Ravelli A;
Ann Rheum Dis; 2014 Jul; 73(7):1380-3. PubMed ID: 24347571
[TBL] [Abstract][Full Text] [Related]
20. Proposed Core Set of Items for Measuring Disease Activity in Systemic Juvenile Idiopathic Arthritis.
Limenis E; Feldman BM; Achonu C; Batthish M; Lang B; Mclimont M; Ota S; Ramanan A; Scuccimarri R; Young NL; Schneider R
J Rheumatol; 2018 Jan; 45(1):115-121. PubMed ID: 28765240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
